Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes.

Meggan MackayMaria Dall'EraJoanna FishbeinKenneth KalunianMartin LesserJorge Sanchez-GuerreroDeborah M LevyEarl SilvermanMichelle A PetriCristina ArriensEdmund J LewisStephen M KorbetFabrizio ContiVladimir TesarZdenka HruskovaEduardo F BorbaEloisa S BonfaTak Mao ChanManish RathiK L GuptaVivekanand JhaSarfaraz A HasniMelissa R WestNeil SolomonsFrederic A HoussiauJuanita Romero-DiazJuan Mejia-ViletBrad H Rovin

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2019)

HITs, derived from short-term kidney responses to treatment, correlate with long-term kidney outcomes, and now must be validated as surrogate end points for LN clinical trials.

Keyphrases

clinical trial
type diabetes
randomized controlled trial
metabolic syndrome
current status
open label
study protocol
replacement therapy
phase iii
smoking cessation